Seeking Alpha

La Jolla Pharma +22.4% AH. Wedbush starts at Outperform.

  • Wedbush's Liana Moussatos has started coverage on La Jolla Pharma (LJPC) with an Outperform and $27 PT.
  • Moussatos sees a "70% probability of a positive outcome" for a Phase 2a trial of La Jolla's GCS-100 drug in March, and thinks the drug could see peak annual sales of $1B.
Comments (4)
  • millsy1
    , contributor
    Comments (96) | Send Message
     
    Still need phase 2 results but nice to see some coverage by wedbush and noble(both have buy ratings)
    25 Feb, 06:04 PM Reply Like
  • cksinvestments
    , contributor
    Comments (7) | Send Message
     
    Wonderful, thank you Liana.
    25 Feb, 07:45 PM Reply Like
  • Stealthe
    , contributor
    Comments (70) | Send Message
     
    Baker Brothers must might smiling right now.... 10% stake
    25 Feb, 10:10 PM Reply Like
  • Patent News
    , contributor
    Comments (1321) | Send Message
     
    what price did baker brothers get in?
    28 Feb, 03:16 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector